Berberine: Benefits, Forms, Dosing, and Drug Interactions

Berberine is a bright yellow alkaloid compound found in barberry, Oregon grape, goldenseal, and Chinese goldthread. It has attracted significant research interest for metabolic conditions — type 2 diabetes, elevated cholesterol, metabolic syndrome, and fatty liver disease. While some studies show modest benefits for blood sugar and cholesterol, the evidence is mixed and effect sizes are far smaller than pharmaceutical alternatives. Berberine also has notable drug interactions and serious safety concerns including rare cardiac arrhythmias.

Internet claims of berberine as "nature's Ozempic" are misleading. Semaglutide (Ozempic/Wegovy) reduces fasting glucose by approximately 22–29 mg/dL and body weight by 16%, whereas berberine has been shown to reduce fasting glucose by only about 4 mg/dL and has not consistently demonstrated meaningful weight loss in rigorous studies.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Berberine is a bright yellow alkaloid found naturally in several plant families, including Berberidaceae (barberry, Oregon grape), Ranunculaceae (Chinese goldthread, Coptis chinensis), Papaveraceae (greater celandine), and Rutaceae (Amur cork tree). It is classified as a quaternary ammonium salt belonging to the protoberberine subclass of isoquinoline alkaloids. The compound appears as a yellow crystalline solid, exhibits low solubility in water, and displays strong yellow fluorescence under ultraviolet light — a property that led to its historical use as a natural dye [2].

Berberine has been used in traditional medicine systems for over 3,000 years. In Traditional Chinese Medicine, berberine-containing plants were prescribed for digestive disorders including diarrhea and dysentery, infections, and inflammatory conditions. Berberine has been approved as an over-the-counter medication in China since the 1950s for treating acute bacterial diarrhea, particularly infections caused by Escherichia coli and Shigella species [2].

In the United States, berberine is classified as a dietary supplement — not approved by the FDA as a pharmaceutical drug and not recognized as Generally Recognized as Safe (GRAS). In the European Union, berberine holds unauthorized novel food status, with the European Food Safety Authority (EFSA) safety assessment still ongoing as of late 2025 [2]. These classifications limit berberine to supplement form, prohibiting disease treatment claims without clinical approval.

Modern research interest centers on berberine's effects on blood sugar regulation, cholesterol levels, and metabolic syndrome. Berberine activates AMP-activated protein kinase (AMPK), a key cellular energy sensor that promotes glucose uptake and inhibits hepatic gluconeogenesis. It also inhibits PCSK9 expression in liver cells, stabilizing LDL receptors on cell surfaces and promoting cholesterol clearance from circulation. Additionally, berberine modulates the gut microbiota and suppresses the NF-kB inflammatory pathway [2][3].

Despite these promising mechanisms, berberine's clinical utility is limited by very poor oral bioavailability — only about 0.5% of an oral dose is absorbed from the small intestine, with an elimination half-life of approximately 4–6 hours and excretion predominantly via the fecal route [1][4].

Forms and Bioavailability

Berberine supplements are available in several chemical forms and delivery systems, each with different characteristics. The fundamental challenge across all forms is berberine's extremely poor oral bioavailability — approximately 0.5% of an oral dose reaches systemic circulation [1][4].

Standard Forms

Form	Berberine Content	Notes
Berberine HCl (Hydrochloride)	~90.4%	Most common supplement form. Used in the majority of clinical trials [1].
Berberine Sulfate	~87.5%	Alternative salt form. Used in some clinical studies including the Zhang 2008 diabetes trial [1][6].
Berberine Chloride	Similar to HCl	Sometimes listed interchangeably with berberine HCl on supplement labels [4].

Most published clinical studies cite the dose of berberine hydrochloride, though they tend to refer to it simply as "berberine." The amounts shown on supplement labels are not pure berberine — 90.4% of berberine HCl is berberine, and 87.5% of berberine sulfate is berberine — but most clinical studies state doses in terms of these same chemical forms [1].

Enhanced-Absorption Formulations

Several formulations have been developed to overcome berberine's poor absorption:

• Berberine Phytosome (Berbevis): A phospholipid complex developed by Indena SpA (Italy) that combines berberine with lecithin as a solubilizer. The formulation is 28–34% berberine and also includes pea protein and grape seed extract, intended to counteract P-glycoprotein efflux. A company-funded study in 11 healthy adults showed berberine bioavailability over 24 hours was approximately 5–10 times higher with Berbevis than standard berberine HCl, depending on dose. However, the study did not involve taking berberine with food, which could potentially have equalized the findings (Petrangolini, Evid Based Complement Alternat Med 2021) [1][4].
• Dihydroberberine (GlucoVantage): A reduced derivative with greater lipophilicity that rapidly converts to berberine after absorption. A company-funded study in 5 healthy young men showed that 100 mg and 200 mg doses yielded blood levels that were 7 and 22 times as high, respectively, as 500 mg of regular berberine HCl over a 2-hour measurement period. However, the study did not involve a full meal, the 2-hour bioavailability window was too short, and the formulation had no impact on blood glucose or insulin levels (Moon, Nutrients 2021) [1][4].
• Liposomal Berberine: Lipid vesicle encapsulation that protects berberine from degradation and improves cellular uptake. Human pharmacokinetic studies indicate up to 6-fold increases in absorption (AUC and Cmax) compared to non-liposomal forms [2].
• Berberine plus Silymarin: Several human studies suggest that combining berberine with silymarin (a constituent of milk thistle) may improve berberine's effects, possibly by increasing absorption via P-glycoprotein inhibition. However, the benefits may be due to an additive effect of the two compounds rather than increased berberine bioavailability (Fogacci, Phytother Res 2019) [1].

Key Principles for Form Selection

• Standard berberine HCl with meals remains the best-studied form. The vast majority of clinical trial evidence — including the largest and most rigorous studies — used standard berberine HCl or berberine sulfate, not enhanced formulations [1][6][7].
• Taking with food is critical: All enhanced-absorption studies were conducted in fasted or semi-fasted states. Taking standard berberine with a full meal may substantially narrow the absorption gap with premium formulations, though this has not been directly tested [1][4].
• Absorption does not guarantee efficacy: Dihydroberberine achieved dramatically higher blood levels but showed no impact on blood glucose or insulin in the available study [4]. Higher systemic exposure does not automatically translate to better clinical outcomes.
• Quality variability is a concern: A 2017 analysis of 15 commercial berberine supplements found the average potency was only 75% of the labeled claim, with wide variability (33–100%). Sixty percent of products failed to meet the typical pharmaceutical standard of 90–110% of label claim [2].

Synergistic Combinations

Berberine is frequently combined with other ingredients in supplements targeting blood sugar, lipids, and metabolism:

• Ceylon cinnamon (Cinnamomum verum extract): Clinical trials show that berberine plus cinnamon reduces fasting blood sugar, HbA1c, and LDL cholesterol more effectively than placebo or berberine alone in patients with type 2 diabetes [2].
• Chromium (as picolinate): Enhances insulin signaling; combinations may improve glucose and lipid profiles in metabolic syndrome [2].
• Alpha-lipoic acid (ALA): Supports mitochondrial function and insulin sensitivity; commonly paired for energy and metabolic support [2].
• Trans-resveratrol: Animal and some human studies indicate enhanced lipid-lowering effects through complementary AMPK and sirtuin pathways [2].

Evidence for Benefits

Blood Sugar and Type 2 Diabetes

Berberine's glucose-lowering effects are among the most studied of its clinical applications. The primary mechanism operates through AMPK activation, which promotes glucose uptake into cells and inhibits glucose production in the liver (hepatic gluconeogenesis). Berberine also improves insulin sensitivity by enhancing the body's response to insulin signaling [2][3].

Berberine vs. placebo in type 2 diabetes: An RCT of 116 men and women with type 2 diabetes and elevated cholesterol and/or triglycerides found that 500 mg of berberine twice daily for 3 months significantly improved fasting glucose, postprandial glucose, and HbA1c levels compared to placebo. They also had greater improvements in total cholesterol, LDL cholesterol, and triglycerides (Zhang, J Clin Endocrinol Metab 2008) [1][6].

Berberine vs. metformin: A small 3-month study in newly diagnosed type 2 diabetes found that 500 mg berberine HCl taken before meals 2–3 times daily was as effective as 500 mg of metformin for lowering fasting glucose, postprandial glucose, and HbA1c. Berberine also significantly reduced total and LDL cholesterol and triglyceride levels (Yin, Metabolism 2008) [1][7]. A 2023 systematic review found that while both demonstrated beneficial effects, berberine was superior to metformin for reducing hyperlipidemia and obesity markers, while metformin was more effective for lowering blood glucose [2][8]. A 2025 RCT in newly diagnosed prediabetic patients found berberine reduced fasting plasma glucose from 109.8 mg/dL to 97.2 mg/dL (reduction of 12.6 mg/dL) versus metformin's reduction of 10.8 mg/dL, with fewer GI events in the berberine group (Chaudhary, Int J Basic Clin Pharmacol 2025) [2].

Meta-analyses: A 2022 systematic review and meta-analysis of RCTs in type 2 diabetes found that berberine supplementation significantly reduced HbA1c levels by 0.5–1%, alongside improvements in fasting plasma glucose [2][9]. A 2024 meta-analysis of 50 RCTs confirmed berberine's efficacy in lowering HbA1c and other glycemic markers when used as monotherapy or adjunct therapy, with effects comparable to some oral antidiabetic agents [2][10].

Important limitations: While these results are encouraging, particularly for people with type 2 diabetes who cannot tolerate metformin, berberine should not be considered a replacement for established diabetes medications. Effects are modest compared to pharmaceutical GLP-1 receptor agonists and SGLT2 inhibitors.

Prediabetes and Insulin Resistance

A study of 49 adults with prediabetes (average age 60) taking one 550 mg tablet of Berberine Phytosome (Berbevis, 188 mg berberine per tablet) twice daily with main meals for 8 weeks reduced fasting blood sugar by 4 mg/dL, insulin resistance by 0.45%, total cholesterol by 10 mg/dL, and triglycerides by 12 mg/dL compared to placebo (Rondanelli, Eur Rev Med Pharmacol Sci 2023) [1].

In 24 adults with metabolic syndrome, 500 mg of berberine HCl three times daily with meals for 3 months produced significant decreases in blood sugar (about a 9% reduction) and insulin levels, with a ~3% reduction in waist circumference in women, along with reductions in triglycerides and systolic blood pressure (Perez-Rubio, Metab Syndr Relat Disord 2013) [1].

Recent 2025 meta-analyses confirm berberine significantly reduces triglycerides (weighted mean difference: −0.367 mmol/L), fasting plasma glucose (WMD: −0.515 mmol/L), waist circumference (WMD: −3.270 cm), LDL cholesterol (−0.495 mmol/L), total cholesterol (−0.451 mmol/L), and BMI (−0.435 kg/m²) in metabolic syndrome components, with favorable safety [2].

Cholesterol and Lipids

Berberine's cholesterol-lowering effects operate through a unique mechanism: it inhibits PCSK9 expression in liver cells, which stabilizes LDL receptors on cell surfaces and promotes LDL cholesterol clearance from circulation [2].

Meta-analysis of lipid effects: A 2023 systematic review and meta-analysis of 18 randomized placebo-controlled trials demonstrated that berberine supplementation significantly reduces LDL cholesterol by approximately 0.46 mmol/L (18 mg/dL), total cholesterol by 0.48 mmol/L (19 mg/dL), and triglycerides by 0.34 mmol/L (30 mg/dL), while increasing HDL cholesterol by 0.06 mmol/L (2 mg/dL) [2][11].

Large MASLD trial (Lei 2026): The largest berberine RCT to date — 337 non-diabetic adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) — found that 500 mg berberine HCl twice daily for 6 months did not reduce weight, BMI, waist circumference, or liver fat. However, berberine led to greater reductions in LDL cholesterol (by 7.72 mg/dL) and apolipoprotein B (by 3.86 mg/dL) compared to placebo, and these differences were statistically significant. Berberine also reduced high-sensitivity C-reactive protein (hs-CRP) (Lei, JAMA Netw Open 2026) [1][5].

Combination with red yeast rice: A case report described a patient with statin intolerance and familial hypercholesterolemia already being treated with evolocumab and ezetimibe (which had lowered her LDL from 363 mg/dL to 115 mg/dL). Adding berberine 500 mg plus red yeast rice once daily further lowered her LDL to 68 mg/dL (Parra-Virto, Clin Investig Arterioscler 2018) [1].

Synthesis: The cholesterol-lowering effect of berberine — particularly for LDL cholesterol — is the most consistently demonstrated benefit across studies. The LDL reduction of approximately 7–18 mg/dL is modest compared to statins but may be clinically meaningful for people who are statin-intolerant or seeking adjunctive lipid support.

Weight Loss and Obesity

Berberine has been widely promoted on social media as "nature's Ozempic" due to its metabolic effects and preclinical evidence suggesting it may enhance GLP-1 secretion. However, the clinical evidence for meaningful weight loss is weak.

Large MASLD trial — no weight loss: The most rigorous study to date (Lei, JAMA Netw Open 2026, n=337) found that berberine 1,000 mg/day for 6 months did not significantly reduce weight, BMI, waist circumference, or visceral abdominal fat compared to placebo in non-diabetic individuals with obesity [1][5].

Meta-analysis results: Meta-analyses have shown modest improvements in obesity-related parameters — weighted mean differences ranging from −0.84 kg to −2.07 kg for body weight, −0.25 to −0.47 kg/m² for BMI, and approximately −1 to −2 cm for waist circumference. These effects are more pronounced in overweight or obese individuals with type 2 diabetes or metabolic syndrome at doses of 1–1.5 g/day for more than 8 weeks [2].

Berberine vs. semaglutide: Semaglutide reduces body weight by approximately 16% versus 5.7% for placebo after 68 weeks (Wadden, JAMA 2021). In contrast, berberine achieves approximately 1–3% body weight reduction over 3–6 months in the most favorable analyses, and the largest RCT showed no significant weight loss at all [1][2][5].

Synthesis: The weight loss claims for berberine are largely overhyped. Its primary metabolic benefits appear to be improvements in insulin sensitivity and lipid profiles rather than potent appetite suppression or fat loss. Calling berberine "nature's Ozempic" is misleading.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

An open-label study among 155 people with NAFLD found that 500 mg berberine three times daily for 16 weeks, along with lifestyle intervention, reduced liver fat content by 57.2% compared to 36.4% for lifestyle intervention alone. However, there was no significant improvement in biomarkers of liver injury and the study lacked a placebo control (Yan, PLoS One 2015) [1].

The larger, more recent Lei 2026 study (n=337) found that berberine 1,000 mg/day for 6 months did not decrease liver fat content or liver enzymes AST or ALT compared to placebo in non-diabetic obese individuals with MASLD [1][5].

Synthesis: The evidence for berberine's benefit in NAFLD/MASLD is mixed. The largest and most rigorous trial showed no benefit for liver fat or liver enzymes. Berberine should not be relied upon for NAFLD/MASLD management.

Colorectal Adenoma Prevention

This is one of berberine's more promising and well-studied applications, though all evidence comes from trials conducted in China.

Landmark 2-year trial: A 2-year RCT among more than 800 people aged 18–75 with a history of colorectal adenoma removal found that 300 mg berberine HCl twice daily modestly reduced the risk of developing additional precancerous polyps — 36% in the berberine group versus 47% in the placebo group (Chen, Lancet Gastroenterol Hepatol 2020) [1][13].

Pooled analysis: An analysis combining data from this trial and two other clinical studies in China (total 1,076 participants) found that taking 300 mg berberine twice daily reduced the 1-year recurrence rate of colorectal adenomas by 31% and the 2-year recurrence rate by 25% compared to placebo (Fang, J Ethnopharmacol 2022) [1].

Long-term follow-up: A follow-up study among 648 participants found that the benefit persisted even after supplementation was discontinued — a lower polyp recurrence rate (34.7% vs. 52.1%) and precancerous polyp occurrence rate (63.4% vs. 71.0%) among those who took berberine versus placebo 6 years after supplementation was stopped (Tan, Cell Rep Med 2025) [1][15].

Limitations: All findings are limited to research conducted in China. Whether these results generalize to non-Chinese populations is unknown. Berberine should not replace standard colorectal cancer screening (colonoscopy) or established prevention strategies.

H. pylori Infection

Berberine has traditionally been used as an antibiotic, and some evidence supports its use as an adjunct to standard H. pylori eradication therapy. Some research has shown that taking berberine with triple therapy (clarithromycin, amoxicillin, and esomeprazole) can modestly increase the eradication rate while reducing side effects such as nausea and diarrhea compared to triple therapy alone (Jiang, Evid Based Complement Alternat Med 2018) [1]. Other research found that berberine plus triple therapy eradicates H. pylori about as effectively as triple therapy plus bismuth (Zhang, Medicine 2017) [1].

Polycystic Ovary Syndrome (PCOS)

In women with PCOS, berberine does not appear to improve ovulation, pregnancy, or live births, but it might help reduce insulin resistance, cholesterol, and adjust hormone levels. Clinical trials and meta-analyses indicate that berberine supplementation (typically 1–1.5 g/day) can lead to significant reductions in body weight, BMI, waist circumference, fasting insulin, and androgen levels, while improving lipid profiles. However, evidence comes from relatively small trials and long-term safety requires further confirmation (Xie, Evid Based Complement Alternat Med 2019; Li, Evid Based Complement Alternat Med 2018) [1].

Cardiovascular Effects

Preliminary research suggested that berberine may help reduce premature ventricular contractions (PVCs) in people with ventricular tachyarrhythmia and strengthen heart contractions in people with congestive heart failure (Xia, Chronic Dis Transl Med 2015) [1]. However, berberine has also been reported to trigger polymorphic ventricular tachycardia (PVT), a potentially dangerous arrhythmia, in some individuals (see Safety and Side Effects below). This dual nature means berberine should be used with extreme caution in anyone with cardiac conditions.

Goldenseal

Goldenseal root naturally contains a small amount of berberine (approximately 25 mg per 1,000 mg of root powder). There is no strong clinical evidence to support goldenseal's use in the prevention or treatment of any disease. There is only weak evidence that goldenseal may be helpful for lowering cholesterol, improving blood sugar control, and helping with arrhythmias, congestive heart failure, high blood pressure, dyspepsia, and irritable bowel syndrome [1]. The myth that goldenseal can block a positive drug screen has no evidence to support it [1].

Recommended Dosing

Indication	Dose	Frequency	Duration
Type 2 diabetes	500 mg berberine HCl	2–3 times daily with meals	3+ months
Prediabetes / metabolic syndrome	500 mg	2–3 times daily with meals	2–3 months
Cholesterol reduction	500–1,000 mg	1–2 times daily	3+ months
Colorectal adenoma prevention	300 mg	Twice daily	2 years
H. pylori adjunct therapy	300–500 mg	3 times daily	Duration of antibiotic course
Berberine Phytosome (Berbevis)	550 mg tablet (188 mg berberine)	Twice daily with meals	8 weeks

Practical Dosing Guidance

• Start low, increase gradually: To minimize gastrointestinal side effects, begin with 500 mg once daily and increase to 500 mg two or three times daily over 1–2 weeks [1][2].
• Take with meals: Berberine may cause nausea, bloating, and abdominal pain. Taking smaller, divided doses with food or immediately after eating helps minimize these effects and may improve absorption [1][4].
• Divide doses throughout the day: Given berberine's short half-life of 4–6 hours, dividing the daily dose into 2–3 administrations maintains more consistent blood levels [2].
• Optimal dose range: Clinical research suggests 900–1,500 mg/day (divided into multiple doses) as the effective range for metabolic benefits. Doses at or above 1 g/day appear optimal based on dose-response meta-analyses [2][12].
• Duration: Most clinical studies evaluating metabolic outcomes have lasted 8–16 weeks. Long-term safety data beyond 6–12 months are limited [2].

How to Read a Supplement Label

The weight of the berberine compound and the weight of actual berberine are different:

• 500 mg berberine HCl = approximately 452 mg actual berberine (90.4%)
• 500 mg berberine sulfate = approximately 438 mg actual berberine (87.5%)

Most clinical studies state doses as the salt form (berberine HCl or berberine sulfate), and supplement labels typically do the same. This makes comparing clinical evidence to supplement labels relatively straightforward [1].

Berberine should be expected to be yellow in color and, if tasted, bitter — these characteristics can help verify that a product actually contains berberine [1].

Safety and Side Effects

Common Side Effects

The most common adverse effects of berberine are gastrointestinal: diarrhea, nausea, constipation, flatulence, and abdominal pain. In clinical trials lasting more than three months, the incidence of gastrointestinal issues has ranged from 10% to 34%, with specific rates of 10.3% for diarrhea, 6.9% for constipation, and 19% for flatulence reported in one 13-week study in type 2 diabetes patients [2]. These effects are typically mild, transient, and most prominent during the initial weeks of treatment [2].

Taking smaller, divided doses with food or immediately after eating helps minimize gastrointestinal symptoms. Starting with a lower dose and gradually increasing is recommended [1][2].

Serious Adverse Effects

Polymorphic ventricular tachycardia (PVT): Berberine has been reported to induce PVT, a potentially life-threatening irregular heart rhythm, possibly due to berberine's inhibition of potassium channels in heart cells, which can delay cardiac repolarization. Three published case reports describe this occurring in older adults with type 2 diabetes:

• A 92-year-old man developed PVT and loss of pulse requiring defibrillation two weeks after beginning berberine (in addition to metformin and lisinopril) (Mesmin, Clinical Toxicology 2024) [1].
• A 76-year-old woman developed PVT soon after increasing her berberine dose (Han, J Am Coll Cardiol 2025) [1].
• A 62-year-old woman who had been taking an unusually high daily dose of berberine (11 grams) for two months experienced cardiac arrest. Low blood calcium (hypocalcemia) was also considered a contributing factor (Itani, J Am Coll Cardiol 2025) [1].

Hyperbilirubinemia and jaundice: Berberine can increase bilirubin levels in the blood by displacing bilirubin from albumin binding sites, potentially causing jaundice. This effect is particularly dangerous in newborns and infants, where elevated bilirubin can cause bilirubin-induced brain dysfunction (kernicterus). Berberine is contraindicated in pregnancy and nursing [1].

Skin reactions: A 54-year-old man developed a severe, burning, red rash in the groin/trunk and underarm area (symmetrical drug-related intertriginous and flexural exanthema, or SDRIFE) after taking 1,200 mg of berberine HCl daily for two months. The rash resolved completely two weeks after stopping berberine (Labadie, Int J Dermatol 2018) [1].

Hypoglycemia risk: Berberine can lower blood sugar, and when combined with antidiabetic medications (insulin, sulfonylureas, metformin), the additive effect may cause dangerously low blood sugar [1][2].

Hypotension: Berberine may lower blood pressure, which could be problematic for people with already low blood pressure or those taking antihypertensive medications [1][2].

Potential DNA Damage

Laboratory studies suggest that berberine may cause DNA damage at high concentrations. Exposing human liver cells to berberine at 3.125 mcmol/L or more (several times higher than the 0.9 mcmol/L achievable in blood with regular supplementation) caused time- and dose-dependent breakage of DNA double strands. Berberine did not damage DNA by directly interacting with it, but by inhibiting topoisomerase II, an enzyme that cuts and repairs tangled DNA strands. This mechanism is similar to certain anticancer drugs (e.g., etoposide) that have been linked with secondary malignancies. This has not been demonstrated to occur at typical supplement doses, but it represents a theoretical concern for long-term use (Chen, Toxicol Lett 2013) [1].

Effects on Gut Microbiome

Berberine may affect the relative abundance of gut bacteria, with mixed clinical implications. A study in people with type 2 diabetes showed that 1,200 mg of berberine daily for 12 weeks depleted bacteria involved in converting polysaccharides into simple sugars. However, berberine also depleted beneficial Bifidobacterium species and increased the relative abundance of multiple Proteobacteria (which tend to be overabundant in metabolic disorders and inflammatory bowel disease) (Zhang, Nat Commun 2020) [1].

Hemolytic Anemia

Berberine should be avoided in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it may trigger hemolytic anemia [2].

Pregnancy and Breastfeeding

Berberine should not be taken by women who are pregnant or nursing. It can cross the placenta and pass into breast milk. The primary concern is elevated bilirubin levels in infants, which can cause kernicterus (bilirubin encephalopathy). Major resources including MotherToBaby and LactMed (National Library of Medicine) classify berberine as likely unsafe or advise avoidance during breastfeeding [1][2].

Goldenseal Safety

Goldenseal root contains berberine at low concentrations, so the cautions above also apply. Goldenseal should not be used by pregnant or nursing women or young children, and its safety has not been established for those with severe liver or kidney disease [1].

A small study in people with type 2 diabetes showed that taking goldenseal (3.3 grams containing 95 mg berberine) 30 minutes before metformin reduced metformin absorption from the gut (Nguyen, Clin Transl Sci 2025). It may be best to avoid taking goldenseal if taking metformin [1].

An organic goldenseal root powder supplement was recalled in August 2020 due to potential contamination with pathogenic microorganisms including Enterobacter cloacae, Cronobacter sakazakii, and Cronobacter dublinensis. The death of an infant was associated with use of the product [1].

Drug Interactions

Berberine inhibits several liver enzymes and transport proteins involved in drug metabolism, which can significantly alter blood levels of many medications. These interactions are clinically important and should be carefully considered before combining berberine with any prescription medications.

Cytochrome P450 Enzyme Inhibition

A clinical study confirmed that repeated berberine administration (300 mg three times daily for 2 weeks) significantly reduced the activities of CYP2D6, CYP2C9, and CYP3A4 (Guo, Eur J Clin Pharmacol 2012) [1].

CYP3A4 substrates — increased blood levels possible:

• Immunosuppressants: cyclosporine — berberine increased cyclosporine AUC by approximately 35% in renal transplant recipients (Wu, Eur J Clin Pharmacol 2005) [1]
• Statins: atorvastatin (Lipitor), lovastatin (Mevacor), simvastatin (Zocor) — elevated statin levels increase risk of myopathy
• Benzodiazepines: midazolam — berberine at 300 mg three times daily increased midazolam AUC by approximately 40%
• PDE5 inhibitors: sildenafil (Viagra), tadalafil (Cialis) — elevated concentrations increase risk of hypotension
• Antibiotics: clarithromycin (Biaxin)

CYP2C9 substrates — increased blood levels possible:

• Anticoagulants: warfarin (Coumadin), apixaban (Eliquis), rivaroxaban (Xarelto)
• Cholesterol drugs: rosuvastatin (Crestor)
• Blood pressure drugs: losartan (Cozaar)
• Anti-inflammatory drugs: ibuprofen (Advil, Motrin), celecoxib (Celebrex), diclofenac (Voltaren)

CYP2D6 substrates — increased blood levels possible:

• Beta-blockers: metoprolol (Lopressor, Toprol XL)
• Antidepressants: paroxetine (Paxil), venlafaxine (Effexor)
• Antipsychotics: risperidone (Risperdal)
• Pain medications: tramadol (Ultram), codeine
• Anti-nausea: ondansetron (Zofran)

P-glycoprotein Inhibition

Berberine inhibits P-glycoprotein (P-gp), an efflux transporter that limits drug absorption in the intestine. This can increase the bioavailability of P-gp substrates:

• Digoxin: In rat studies, oral berberine raised digoxin AUC by 33–70%, potentially heightening digoxin toxicity risk. Digoxin has a narrow therapeutic index, making this interaction particularly concerning [2].
• Antiretrovirals: HIV protease inhibitors are P-gp substrates; berberine may elevate their levels [2].
• Metformin: Berberine may enhance intestinal absorption of metformin through transporter modulation, contributing to synergistic glucose-lowering effects but also increasing hypoglycemia risk [2].

Blood Sugar-Lowering Medications

Berberine should not be taken with medications that lower blood sugar, including insulin, glimepiride (Amaryl), pioglitazone (Actos), sulfonylureas, and others, as the additive hypoglycemic effect could be dangerous [1][2]. There is limited clinical evidence on combining berberine with GLP-1 agonists (including semaglutide and tirzepatide). Both lower blood glucose, potentially increasing hypoglycemia risk. No large-scale human trials confirm the safety or efficacy of this combination [2].

Key Drug Interaction Summary

Interaction Type	Mechanism	Medications Affected	Clinical Significance
CYP3A4 inhibition	Reduced drug metabolism	Cyclosporine, statins, midazolam, sildenafil, clarithromycin	High — documented 35–40% AUC increases
CYP2C9 inhibition	Reduced drug metabolism	Warfarin, losartan, ibuprofen, rosuvastatin	Moderate-High — bleeding risk with anticoagulants
CYP2D6 inhibition	Reduced drug metabolism	Metoprolol, paroxetine, tramadol, codeine	Moderate
P-gp inhibition	Increased drug absorption	Digoxin, antiretrovirals	High — digoxin has narrow therapeutic index
Additive hypoglycemia	Both lower blood sugar	Insulin, sulfonylureas, metformin, GLP-1 agonists	High — monitor closely
Additive hypotension	Both lower blood pressure	Antihypertensives	Moderate
Bilirubin displacement	Competes for albumin binding	Jaundice-inducing medications, all drugs in neonates	High in neonates

Consult a healthcare provider before combining berberine with any medication.

Dietary Sources

Berberine is not obtained through typical dietary foods. It is found exclusively in specific medicinal plants, primarily in their roots, rhizomes, and bark.

Plant	Common Name	Notes
Berberis vulgaris	Common barberry	Berberidaceae family; variable berberine content in root bark
Mahonia aquifolium	Oregon grape	Moderate berberine; root and rhizome
Coptis chinensis	Chinese goldthread	2.76–8%+ berberine in rhizome; primary commercial source
Hydrastis canadensis	Goldenseal	~2.5% berberine (~25 mg per 1,000 mg root powder)
Phellodendron amurense	Amur cork tree	Variable; Rutaceae family; found in bark

Goldenseal root powder provides approximately 25 mg of berberine per 1,000 mg, making it an impractical and uneconomical source. To achieve clinical berberine doses (500–1,500 mg/day), one would need to consume 20–60 grams of goldenseal root powder daily. The only practical way to obtain berberine at the doses used in clinical studies is through supplementation with concentrated berberine extracts [1].

References

1. ConsumerLab. "Berberine & Goldenseal Supplements Review." Accessed 2026. consumerlab.com/reviews/berberine-goldenseal-supplements-review/berberine/
2. Grokipedia. "Berberine." grokipedia.com/page/Berberine
3. National Center for Complementary and Integrative Health (NCCIH). "Goldenseal." nccih.nih.gov/health/goldenseal
4. Petrangolini G et al. "A New Food-Grade Formulation of Berberine with Improved Bioavailability." Evid Based Complement Alternat Med. 2021. doi: 10.1155/2021/9996371
5. Lei Y, et al. "Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial." JAMA Netw Open. 2026. jamanetwork.com/journals/jamanetworkopen/fullarticle/2830825
6. Zhang Y, Li X, Zou D, et al. "Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine." J Clin Endocrinol Metab. 2008;93(7):2559-2565. doi: 10.1210/jc.2007-2404
7. Yin J, Xing H, Ye J. "Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus." Metabolism. 2008;57(5):712-717. doi: 10.1016/j.metabol.2008.01.013
8. Fogacci F et al. "Berberine and silymarin combination." Phytother Res. 2019.
9. 2022 systematic review and meta-analysis of RCTs evaluating berberine in type 2 diabetes.
10. 2024 meta-analysis of 50 RCTs confirming berberine's efficacy in lowering HbA1c and glycemic markers.
11. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia. Systematic review and meta-analysis of 18 RCTs. 2023.
12. Zamani M, et al. "The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis of 49 RCTs." 2022.
13. Chen H, et al. "Berberine for the Prevention of Colorectal Adenoma Recurrence: A Randomized Clinical Trial." Lancet Gastroenterol Hepatol. 2020. doi: 10.1016/S2468-1253(19)30405-9
14. Fang C, et al. "Berberine for prevention of colorectal adenoma recurrence: A pooled analysis." J Ethnopharmacol. 2022. doi: 10.1016/j.jep.2021.114916
15. Tan Y, et al. "Long-term effects of berberine on colorectal adenoma recurrence after discontinuation." Cell Rep Med. 2025.
16. Jiang HY, et al. "The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication." Evid Based Complement Alternat Med. 2018. doi: 10.1155/2018/6921378
17. Zhang MZ, et al. "Berberine plus triple therapy versus bismuth plus triple therapy for H. pylori eradication." Medicine. 2017. doi: 10.1097/MD.0000000000008899
18. Xie L, et al. "Berberine for polycystic ovary syndrome: A systematic review and meta-analysis." Evid Based Complement Alternat Med. 2019.
19. Li L, et al. "Berberine for polycystic ovary syndrome." Evid Based Complement Alternat Med. 2018.
20. Xia LM, Luo MH. "Study progress of berberine for treating cardiovascular disease." Chronic Dis Transl Med. 2015. doi: 10.1016/j.cdtm.2015.11.006
21. Li GH, et al. "Berberine prevents radiation-induced intestinal injury." Med Oncol. 2010.
22. RCT in Chinese men with hyperlipidemia, berberine 500 mg twice daily for 12 weeks, testosterone increase. 2021. pubmed.ncbi.nlm.nih.gov/39690297/
23. Mandal SK, et al. "An updated pharmacology of goldenseal (Hydrastis canadensis)." Pharmacol Res. 2020.
24. Chen S, et al. "Berberine-induced DNA damage via topoisomerase II inhibition." Toxicol Lett. 2013.
25. Mesmin S, et al. "Berberine-induced polymorphic ventricular tachycardia in a 92-year-old." Clinical Toxicology. 2024.
26. Han S, et al. "Berberine-associated polymorphic ventricular tachycardia." J Am Coll Cardiol. 2025.
27. Itani R, et al. "Cardiac arrest associated with high-dose berberine and hypocalcemia." J Am Coll Cardiol. 2025.
28. Chan E. "Displacement of bilirubin from albumin by berberine." Biol Neonate. 1993.
29. Labadie JG, et al. "SDRIFE caused by berberine." Int J Dermatol. 2018.
30. Zhang X, et al. "Berberine alters gut microbiota in type 2 diabetes." Nat Commun. 2020. nature.com/articles/s41467-020-18213-x
31. Guo Y, et al. "Repeated administration of berberine inhibits cytochromes P450 in humans." Eur J Clin Pharmacol. 2012. doi: 10.1007/s00228-011-1108-2
32. Wu X, et al. "Effects of berberine on cyclosporin A blood concentration in renal transplant recipients." Eur J Clin Pharmacol. 2005. doi: 10.1007/s00228-005-0975-6
33. Moon JM, et al. "Pharmacokinetics of Dihydroberberine and GlucoVantage Compared to Berberine." Nutrients. 2021. doi: 10.3390/nu13082066
34. Nguyen TA, et al. "Goldenseal reduces metformin absorption." Clin Transl Sci. 2025.